BACKGROUND: Analyses of secondary data (e.g., insurance claims) togenerate real-world evidence often entail use of algorithms to identify,define, and study key measures (e.g., diagnosis [dx] date; receipt oftherapy).OBJECTIVE: To systematically assess the validity of claims data-basedalgorithms used to identify multiple myeloma (MM) dx and treatmentrelatedmeasures.METHODS: A retrospective, observational study was conducted usingclaims data from Geisinger Health (GH), an integrated health caredelivery system in Pennsylvania. In a cohort of patients with MM fromJanuary 2004-November 2016, algorithms were used to identify anddefine measures related to dx and ensuing therapy. Measures fromclaims data were adjudicated against a medical record review (MRR)to evaluate the validity of the claims-based algorithms. Validity ofclaims-based study measures were evaluated by assessing positive predictivevalues (PPV) and proportions. PPV was calculated as the numberof true-positives divided by the sum of true- and false-positives.RESULTS: Of 352 patients with 2 MM dx claims 30 days apart, MRRwas conducted for 177 patients who met other selection criteria (e.g.,12-month pre-index period without MM dx). Most (68.9%) were 65years old and 54.8% were male. Of the patients reviewed, 131 hada confirmed MM dx, per the MRR, with a PPV of 74.0% (95% CI:67.680.5%). Among these, 84.7% (95% CI: 78.6-90.9%) of patientshad an initial MM dx date from claims within 30 days of the initialMM dx date ascertained from the MRR. From the MRR, 89.3% ofpatients were confirmed to receive first-line (1L) therapy versus 82.4%of patients identified using the claims-based algorithms. The resultingPPV was 94.4% (95% CI: 90.1-98.8%). Based on the claims-based algorithms,56.5%, 22.2%, and 21.3% of patients received doublet, steroidonly, and triplet regimens, respectively. The MRR showed that 63.3%,26.5%, and 6.8% received doublet, triplet, and steroid only regimens,respectively. The proportion having the same 1L regimens identifiedfrom claims and MRR was 66.7% (95% CI: 57.8-75.6%); those withthe same bortezomib- or lenalidomide-based 1L regimens was 77.8%(95% CI: 68.2-87.4%). Among patients receiving 1L therapy, 45.4%and 48.7% had evidence of progression from claims and MRR, respectively(resulting PPV: 63.3% [95% CI: 49.8-76.8%]).CONCLUSIONS: Using GH data, the claims-based algorithms hada PPV/proportion of >70% for identifying true MM dx, receipt of1L therapy, and 1L bortezomib- or lenalidomide-based regimens.Previous validation studies have reported similar PPVs.
Administrative data algorithms to identify diagnosis and treatment-related measures in patients with multiple myeloma
A validation study
Parikh, R., Clancy, Z., Candrilli, S., & Parikh, K. (2018). Administrative data algorithms to identify diagnosis and treatment-related measures in patients with multiple myeloma: A validation study. Journal of Managed Care and Specialty Pharmacy, 24(4-a Suppl), S29. [C21]. https://doi.org/10.18553/jmcp.2018.24.4-a.s1
Abstract
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Recent Publications
OCCASIONAL PAPER
OCCASIONAL PAPER
Culturally informed community engagement
Article
Does the relationship between alcohol retail environment and alcohol outcomes vary by depressive symptoms? Findings from a US Survey of Black, Hispanic and White drinkers
Article